Pharmaceutical

Ipsen’s Elafibranor gains MHRA approval for PBC treatment

Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.

Oct 10, 2024 - 04:00
Ipsen’s Elafibranor gains MHRA approval for PBC treatment
Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.
Read the original article

Tags:

Previous Article

City Therapeutics launches with $135m Series A funding

Next Article

Magazine: Cell and gene therapy approvals drive paradigm change in manufacturing

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Digital health startups need more doctor CEOs

Opinion: Digital health startups need more doctor CEOs

Nov 9, 2023

Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma

Janssen’s BALVERSA receives EC approval for metastatic ...

Aug 27, 2024

CDC to cut back on Covid data it collects as public health emergency ends

CDC to cut back on Covid data it collects as public hea...

May 5, 2023